Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: Response and survival

International Journal of Oncology

Volumn 13, Issue 3, 1998, Pages 589-594

  Heys, Steven D ^a,b   Ogston, Keith N ^a   Simpson, William G ^a   Walker, Leslie G ^a   Hutcheon, Andrew W ^a   Sarkar, Tarun K ^a   Eremin, Oleg ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Acute phase proteins; Advanced breast cancer; Neoadjuvant chemotherapy

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; ALPHA 1 ANTITRYPSIN; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; TRANSFERRIN; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031854751     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.3.589     Document Type: Article

References (35)

1. Cancer Research Campaign: Breast cancer - UK. Fact sheet 6: 1, 1996.
2. Rubens RD: The management of locally advanced breast cancer. Br J Cancer 65: 145-147, 1992.
3. Heys SD, Eremin JM, Sarkar TK, Hutcheon AW, Ah-See AK and Eremin O: Role of multimodality therapy in the management of locally advanced breast carcinoma. J Am Coll Surg 179: 493-504, 1994.
4. Jacquillat CJ, Weil M, Baillet F, Borel C, Auclerc G, De Maublanc MA, Housett M, Forget G, Thill L, Soubrane C and Khayat D: Results of neoadjuvant chemotherapy and radiation in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119-129, 1990.
5. Morrow M, Braverman A, Thelmo W, et al: Multimodal therapy for locally advanced breast cancer. Arch Surg 121: 1291-1296, 1986.
6. Hortobagyi G, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, McBride CM, Martin RG and Montague E: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507-2516, 1988.
7. Piccart MJ, De Valeriola D, Paridaens R, Balikdjian D, Mattheiem WH, Loriaux C, Arrigo C, Cantraine F and Heuson J-C: Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer 62: 2501-2506, 1988.
8. Remvikos Y, Mosseri V, Zajdela A, Voillemot N, Magdelenat H and Pouillart P: Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann NY Acad Sci 698: 193-203, 1993.
9. Scholl SM, Pierga JY, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangie T, Remvikos Y, Durand JC, Fourquet A and Pouillart P: Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31 A: 1969-1975, 1995.
10. Berry WR, Laszlo J, Cos E, Walker A and Paulson D: Prognostic factors in metastatic and hormonally responsive carcinoma of the prostate. Cancer 44: 763-765, 1979.
11. Sirrot MN, Bajorin DF, Wong GYC, Tao Y, Chapman PB, Templeton MA and Houghton AN: Prognostic factors in patients with metastatic malignant melanoma. Cancer 72: 3091-3098, 1993.
12. Heys SD, Walker LG, Deehan DJ and Eremin O: Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg J R Coll Surg Ed 43: 163-168, 1998.
13. O'Quigley J, Haworth S, Cooper EH, Haije W, van der Werf-Messing B, Richards B and Robinson MRG: Prognostic significance of serum proteins in invasive bladder cancer. Eur J Cancer 17: 251-255, 1981.
14. De Mello J, Struthers L, Turner R, Cooper EH, Giles GR and the Yorkshire Regional Gastrointestinal Cancer Research Group: Multivariate analyses as aids to the diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer 48: 341-348, 1983.
15. McMillan DC, Wotherspoon HA, Fearon KCH, Sturgeon C, Cooke TG and McArdle CS: A prospective study of tumour recurrence and the acute phase response after apparently curative colorectai cancer surgery. Am J Surg 170: 319-322, 1995.
16. Simpson WG, Heys SD, Whiting PH, Eremin O and Broom J: Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin Exp Imunol 99: 143-147, 1995.
17. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
18. Sternberg JC: A rate nephelometer for measuring specific proteins by immunoprecipitation. Clin Chem 23: 1456-1464, 1977.
19. Mantel N: Evaluation of survival data and two new rank statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1986.
20. Cox DK: Regression models and life tables (with discussion). J R Stat Soc 34: 187-220, 1972.
21. Christensen E: Multivariate survival analysis using Cox's regression model. Hepatology 7: 1346-1358, 1987.
22. Haybittle JL, Blarney RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI and Griffiths K: A prognostic index in primary breast cancer. Br J Cancer 45: 361-366, 1982.
23. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blarney RW and Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Surg 56: 489-492, 1987.
24. Eltahir A, Heys SD, Hutcheon AW, Sarkar TK, Smith I, Walker LG, Ah-See AK and Eremin O: Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 175: 127-132, 1998.
25. Robertson JFR, Pearson D, Price MR, Selby C, Badley RA, Pearson J, Blarney RW and Howell A: Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer 26: 1127-1132, 1990.
26. Robertson JFR, Pearson D, Price MR, Selby C, Pearson J, Blarney RW and Howell A: Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother 33: 403-410, 1991.
27. Robertson JFR, Pearson D, Price MR, Selby C, Blarney RW and Howell A: Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer 64: 757-763, 1991.
28. Marinkovic S, Jahreis GP, Wong GG and Baumann H: IL-6 modulates the synthesis of a specific set of acute phase proteins. J Immunol 142: 808-812, 1989.
29. Fischer JE and Hasselgren P-O: Cytokines and glucocorticoids in the regulation of the hepato-skeletal axis in sepsis. Am J Surg 161: 266-271, 1991.
30. Gewurz HC, Mold J, Siegel J and Fiedel B: C-reactive protein and the acute phase response. Adv Intern Med 27: 345-372, 1982.
31. Ballou SP and Kushner I: C-reactive protein and the acute phase response. Adv Intern Med 37: 313-336, 1992.
32. Ljunberg B, Grankvist K and Rasmuson T: Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 76: 1435-1439, 1995.
33. Falconer JS, Slater C, Ross JA, Preston T and Fearon KCH: Albumin synthetic rates, the acute phase response and cytokines in pancreatic cancer. Br J Surg 82: 682, 1995.
34. Heys SD, Kernohan NM, Murray JB, Walker F and Eremin O: Expression of the intermediate affinity interleukin 2 receptor by a human solid tumour cell line: evidence for functional activity. Int J Oncol 5: 931-935, 1994.
35. Wigmore SJ, Ross JA, Fearon KCH, Maingay JP and Carter DC: Pancreatic cancer cells stimulate C-reactive protein production in isolated hepatocytes via IL6 or ILS. Br J Surg 81: 184, 1994.